Download PDF
J Reconstr Microsurg 2012; 28(01): 07-20
DOI: 10.1055/s-0031-1285988
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Impact of Current Immunosuppression Strategies in Renal Transplantation on the Field of Reconstructive Transplantation

Jeff Chang
1   Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Washington, Seattle, Washington
,
Connie L. Davis
2   Department of Medicine, University of Washington, Seattle, Washington
,
David W. Mathes
1   Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Washington, Seattle, Washington
› Author Affiliations
Further Information

Publication History

16 May 2011

30 May 2011

Publication Date:
12 August 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Composite tissue allograft (CTA) transplantation, such as the clinical face and hand transplants, has now been performed in multiple centers across the world. The transplants have successfully treated complex injuries that have either failed conventional approaches or where autologous reconstruction could not restore both form and function. CTA transplantation has the potential to improve outcomes over traditional techniques. However, the widespread application of CTA transplantation continues to be limited by the need for chronic immunosuppression. Due to the small numbers of CTA transplants performed, any modification in the immunosuppression used will likely be based from the solid organ literature. The renal transplantation literature has served as the basis for the current selection of CTA drug regimens and in this article we review the evidence in the renal transplant literature for the selection of immunosuppressive regimens. The study then compares the regimens used in both the face and hand transplantation with those regimens currently used for renal transplantation.

Keywords

Immunosuppression - composite tissue allotransplantation - face transplantation
 

  • References

  • 1 Garcia VD, Carvalho DB, Gonçalves RT , et al. Randomized trial of early corticosteroid reduction vs. regular-dose corticosteroid maintenance in combination with tacrolimus and mycophenolate mofetil in living donor kidney transplant recipients: the Brazilian CORRETA trial. Clin Transplant 2010; 24 (4) E109-E115
    CrossrefPubMedGoogle Scholar
  • 2 Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc 1956; 160 (4) 277-282
    CrossrefPubMedGoogle Scholar
  • 3 Whitaker IS, Duggan EM, Alloway RR , et al. Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons. J Plastic Reconstr Aesthet Surg 2008; 61 (5) 481-492
    PubMedGoogle Scholar
  • 4 Forsythe JL. ATG—a polyclonal sledgehammer?. Transpl Immunol 1994; 2 (2) 148-152
    CrossrefPubMedGoogle Scholar
  • 5 Vincenti F, Kirkman R, Light S , et al. Daclizumab Triple Therapy Study Group Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338 (3) 161-165
    CrossrefPubMedGoogle Scholar
  • 6 Hardinger KL, Rhee S, Buchanan P , et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008; 86 (7) 947-952
    CrossrefPubMedGoogle Scholar
  • 7 Cantarovich M, Durrbach A, Hiesse C, Ladouceur M, Benoit G, Charpentier B. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. Transplantation 2008; 86 (12) 1732-1737
    CrossrefPubMedGoogle Scholar
  • 8 Tian JH, Wang X, Yang KH, Liu AP, Luo XF, Zhang J. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. Transplant Proc 2009; 41 (9) 3671-3676
    CrossrefPubMedGoogle Scholar
  • 9 Calne R, Friend P, Moffatt S , et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351 (9117) 1701-1702
    PubMedGoogle Scholar
  • 10 Ciancio G, Burke III GW. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8 (1) 15-20
    PubMedGoogle Scholar
  • 11 Farney A, Sundberg A, Moore P , et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008; 22 (1) 41-49
    PubMedGoogle Scholar
  • 12 Schadde E, D'Alessandro AM, Knechtle SJ , et al. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl Int 2008; 21 (7) 625-636
    CrossrefPubMedGoogle Scholar
  • 13 Ciancio G, Burke GW, Gaynor JJ , et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008; 22 (2) 200-210
    PubMedGoogle Scholar
  • 14 Ciancio G, Gaynor JJ, Roth D , et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplant Proc 2010; 42 (9) 3503-3506
    CrossrefPubMedGoogle Scholar
  • 15 Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83 (11) 1509-1512
    CrossrefPubMedGoogle Scholar
  • 16 Tan HP, Donaldson J, Basu A , et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009; 9 (2) 355-366
    CrossrefPubMedGoogle Scholar
  • 17 Kandus A, Arnol M, Omahen K , et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Transplantation 2010; 89 (8) 1022-1027
    CrossrefPubMedGoogle Scholar
  • 18 Webster AC, Ruster LP, McGee R , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; (1): CD003897-
    PubMedGoogle Scholar
  • 19 Laftavi MR, Alnimri M, Weber-Shrikant E , et al. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Transplant Proc 2011; 43 (2) 458-461
    CrossrefPubMedGoogle Scholar
  • Immunosuppression Use for Induction. 1999 to 2008 Recipients with Kidney Transplants. (2009). SRTR Database. Retrieved from http://optn.transplant.hrsa.gov/ar2009/506a_ki.htm
    PubMedGoogle Scholar
  • 21 Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331 (7520) 810-
    CrossrefPubMedGoogle Scholar
  • 22 Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81 (9) 1234-1248
    CrossrefPubMedGoogle Scholar
  • 23 Weir MR, Mulgaonkar S, Chan L , et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79 (8) 897-907
    CrossrefPubMedGoogle Scholar
  • 24 Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8 (2) 307-316
    CrossrefPubMedGoogle Scholar
  • 25 Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P ; Astellas Corticosteroid Withdrawal Study Group A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248 (4) 564-577
    PubMedGoogle Scholar
  • 26 Augustine JJ, Hricik DE. Steroid withdrawal: moving on to the next questions. Am J Transplant 2009; 9 (1) 3-4
    CrossrefPubMedGoogle Scholar
  • 27 Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009; 9 (1) 160-168
    PubMedGoogle Scholar
  • 28 Padiyar A, Augustine JJ, Bodziak KA, Aeder M, Schulak JA, Hricik DF. Influence of African-American ethnicity on acute rejection after early steroid withdrawal in primary kidney transplant recipients. Transplant Proc 2010; 42 (5) 1643-1647
    CrossrefPubMedGoogle Scholar
  • 29 Laftavi MR, Stephan R, Stefanick B , et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005; 137 (3) 364-371
    CrossrefPubMedGoogle Scholar
  • 30 Heilman RL, Reddy KS, Mazur MJ , et al. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc 2006; 38 (5) 1307-1313
    CrossrefPubMedGoogle Scholar
  • 31 Heilman RL, Chakkera HA, Reddy KS , et al. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression. Clin Transplant 2008; 22 (3) 309-315
    PubMedGoogle Scholar
  • 32 Heilman RL, Devarapalli Y, Chakkera HA , et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10 (3) 563-570
    CrossrefPubMedGoogle Scholar
  • 33 Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009; (1): CD005632-
    PubMedGoogle Scholar
  • Immunosuppression Use for Induction by Discharge Regimen. 2004 to 2008 Recipients with Kidney Transplants. (2009). SRTR Database. Retrieved from http://optn.transplant.hrsa.gov/ar2009/506b_ki.htm
    PubMedGoogle Scholar
  • 35 Dantal J, Berthoux F, Moal MC , et al; RAD A2420 Study Group. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010; 23 (11) 1084-1093 10.1111/j.1432-2277.2010.01094.x
    CrossrefPubMedGoogle Scholar
  • 36 Devauchelle B, Badet L, Lengelé B , et al. First human face allograft: early report. Lancet 2006; 368 (9531) 203-209
    CrossrefPubMedGoogle Scholar
  • 37 Lantieri L, Meningaud JP, Grimbert P , et al. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet 2008; 372 (9639) 639-645
    CrossrefPubMedGoogle Scholar
  • 38 Guo S, Han Y, Zhang X , et al. Human facial allotransplantation: a 2-year follow-up study. Lancet 2008; 372 (9639) 631-638
    CrossrefPubMedGoogle Scholar
  • 39 Siemionow M, Papay F, Alam D , et al. Near-total human face transplantation for a severely disfigured patient in the USA. Lancet 2009; 374 (9685) 203-209
    CrossrefPubMedGoogle Scholar
  • 40 Pomahac B, Pribaz J, Eriksson E , et al. Restoration of facial form and function after severe disfigurement from burn injury by a composite facial allograft. Am J Transplant 2011; 11 (2) 386-393
    CrossrefPubMedGoogle Scholar
  • 41 Mathew JM, Garcia-Morales R, Fuller L , et al. Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses. Transplantation 2000; 70 (12) 1675-1682
    CrossrefPubMedGoogle Scholar
  • 42 Sheil AG, Moseley RV, Murray JE. Differential skin and renal homograft survival in dogs on immunosuppressive therapy. Surg Forum 1964; 15: 166-168
    PubMedGoogle Scholar
  • 43 Lee WP, Yaremchuk MJ, Pan YC, Randolph MA, Tan CM, Weiland AJ. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991; 87 (3) 401-411
    CrossrefPubMedGoogle Scholar
  • 44 Kuhr CS, Yunusov M, Sale G, Loretz C, Storb R. Long-term tolerance to kidney allografts in a preclinical canine model. Transplantation 2007; 84 (4) 545-547
    CrossrefPubMedGoogle Scholar
  • 45 Dubernard JM, Lengelé B, Morelon E , et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med 2007; 357 (24) 2451-2460
    CrossrefPubMedGoogle Scholar
  • 46 Pellé G, Xu Y, Khoury N, Mougenot B, Rondeau E. Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am J Kidney Dis 2005; 46 (6) 1124-1128
    CrossrefPubMedGoogle Scholar
  • 47 Moren M, Testelin S, Petruzzo P , et al. New Partial Face Allograft Transplantation: Report on First Six Months [Abstract]. American Society for Reconstructive Transplant (ASRT). Chicago, IL; Nov 2010.
    PubMedGoogle Scholar
  • 48 Petruzzo P, Lanzetta M, Dubernard JM , et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation 2010; 90 (12) 1590-1594
    CrossrefPubMedGoogle Scholar
  • 49 Jones JW, Gruber SA, Barker JH, Breidenbach WC. Louisville Hand Transplant Team. Successful hand transplantation. One-year follow-up. N Engl J Med 2000; 343 (7) 468-473
    CrossrefPubMedGoogle Scholar
  • 50 Breidenbach WC, Gonzales NR, Kaufman CL, Klapheke M, Tobin GR, Gorantla VS. Outcomes of the first 2 American hand transplants at 8 and 6 years posttransplant. J Hand Surg Am 2008; 33 (7) 1039-1047
    CrossrefPubMedGoogle Scholar
  • 51 Ravindra KV, Buell JF, Kaufman CL , et al. Hand transplantation in the United States: experience with 3 patients. Surgery 2008; 144 (4) 638-643 discussion 643–644
    CrossrefPubMedGoogle Scholar
  • 52 Dubernard JM, Owen E, Herzberg G , et al. Human hand allograft: report on first 6 months. Lancet 1999; 353 (9161) 1315-1320
    CrossrefPubMedGoogle Scholar
  • 53 Petruzzo P, Revillard JP, Kanitakis J , et al. First human double hand transplantation: efficacy of a conventional immunosuppressive protocol. Clin Transplant 2003; 17 (5) 455-460
    CrossrefPubMedGoogle Scholar
  • 54 Dubernard JM, Petruzzo P, Lanzetta M , et al. Functional results of the first human double-hand transplantation. Ann Surg 2003; 238 (1) 128-136
    CrossrefPubMedGoogle Scholar
  • 55 Petruzzo P, Badet L, Gazarian A , et al. Bilateral hand transplantation: six years after the first case. Am J Transplant 2006; 6 (7) 1718-1724
    CrossrefPubMedGoogle Scholar
  • 56 Jabłecki J, Kaczmarzyk L, Patrzałek D , et al. First Polish Hand Allograft – 6-month report. Pol Przegl Chir 2007; 79 (3) 232-238
    PubMedGoogle Scholar
  • 57 Jablecki J, Kaczmarzyk L, Patrzałek D, Domanasiewicz A, Boratyńska Z. First Polish forearm transplantation: report after 17 months. Transplant Proc 2009; 41 (2) 549-553
    CrossrefPubMedGoogle Scholar
  • 58 Jablecki J, Kaczmarzyk L, Domanasiewicz A, Chelmonski A, Boratynska M, Patrzalek D. First Polish forearm transplantation - final report (outcome after 4 years). Ann Transplant 2010; 15 (2) 61-67
    PubMedGoogle Scholar
  • 59 Cavadas PC, Landin L, Ibañez J. Bilateral hand transplantation: result at 20 months. J Hand Surg Eur Vol 2009; 34 (4) 434-443
    CrossrefPubMedGoogle Scholar
  • 60 Landin L, Cavadas PC, Garcia-Cosmes P, Thione A, Vera-Sempere F. Perioperative ischemic injury and fibrotic degeneration of muscle in a forearm allograft: functional follow-up at 32 months post transplantation. Ann Plast Surg 2011; 66 (2) 202-209
    CrossrefPubMedGoogle Scholar
  • 61 Piza-Katzer H, Ninkovic M, Pechlaner S, Gabl M, Ninkovic M, Hussl H. Double hand transplantation: functional outcome after 18 months. J Hand Surg [Br] 2002; 27 (4) 385-390
    PubMedGoogle Scholar
  • 62 Schneeberger S, Ninkovic M, Piza-Katzer H , et al. Status 5 years after bilateral hand transplantation. Am J Transplant 2006; 6 (4) 834-841
    CrossrefPubMedGoogle Scholar
  • 63 Schneeberger S, Kreczy A, Brandacher G, Steurer W, Margreiter R. Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. Am J Transplant 2004; 4 (8) 1372-1374
    CrossrefPubMedGoogle Scholar
  • 64 Schneeberger S, Ninkovic M, Gabl M , et al. First forearm transplantation: outcome at 3 years. Am J Transplant 2007; 7 (7) 1753-1762
    CrossrefPubMedGoogle Scholar
  • 65 Schneeberger S, Gorantla VS, van Riet RP , et al. Atypical acute rejection after hand transplantation. Am J Transplant 2008; 8 (3) 688-696
    CrossrefPubMedGoogle Scholar
  • 66 Brandacher G, Ninkovic M, Piza-Katzer H , et al. The Innsbruck hand transplant program: update at 8 years after the first transplant. Transplant Proc 2009; 41 (2) 491-494
    CrossrefPubMedGoogle Scholar
  • 67 Petruzzo P, Lanzetta M, Dubernard JM , et al. The international registry on hand and composite tissue transplantation. Transplantation 2008; 86 (4) 487-492
    CrossrefPubMedGoogle Scholar
  • 68 Breidenbach WC. The Louisville Experience. American Society for Reconstructive Transplant (ASRT). Chicago, IL; Nov 2010.
    PubMedGoogle Scholar
  • 69 Landin L, Cavadas PC, Ibañez J, Roger I. Malignant skin tumor in a composite tissue (bilateral hand) allograft recipient. Plast Reconstr Surg 2010; 125 (1) 20e-21e
    PubMedGoogle Scholar
  • 70 Cavadas PC. The Spanish Experience. International Hand and Composite Tissue Allograft Society (IHCTAS). Atlanta, GA; Mar 2011.
    Google Scholar
  • 71 Yusen RD, Shearon TH, Qian Y , et al. Lung transplantation in the United States, 1999-2008. Am J Transplant 2010; 10(4 Pt 2): 1047-1068
    CrossrefPubMedGoogle Scholar
  • 72 Mazariegos GV, Steffick DE, Horslen S , et al. Intestine transplantation in the United States, 1999-2008. Am J Transplant 2010; 10(4 Pt 2): 1020-1034
    CrossrefPubMedGoogle Scholar
  • 73 Foster RD, Fan L, Neipp M , et al. Donor-specific tolerance induction in composite tissue allografts. Am J Surg 1998; 176 (5) 418-421
    CrossrefPubMedGoogle Scholar
  • 74 Siemionow MZ, Izycki DM, Zielinski M. Donor-specific tolerance in fully major histocompatibility major histocompatibility complex-mismatched limb allograft transplants under an anti-alphabeta T-cell receptor monoclonal antibody and cyclosporine A protocol. Transplantation 2003; 76 (12) 1662-1668
    CrossrefPubMedGoogle Scholar
  • 75 Kuo YR, Huang CW, Goto S , et al. Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation. J Surg Res 2009; 153 (2) 317-325
    CrossrefPubMedGoogle Scholar
  • 76 Mathes DW, Randolph MA, Solari MG , et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation 2003; 75 (1) 25-31
    CrossrefPubMedGoogle Scholar
  • 77 Hettiaratchy S, Melendy E, Randolph MA , et al. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation 2004; 77 (4) 514-521
    CrossrefPubMedGoogle Scholar